Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

German orphans flounder: Pfizer pulls Bosulif, calls for "urgent system review"

This article was originally published in Scrip

Executive Summary

Pfizer has won the dubious honor of becoming the first company to withdraw from the German market a product which was deemed to have additional benefit, after failing to agree on a price for orphan cancer drug Bosulif (bosutinib). This latest withdrawal from Germany could set a worrisome precedent for future orphan drugs undergoing early benefit assessment in the country. Pfizer, among others, is calling for an "urgent review" of the procedure.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC023488

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel